Product Details
| Product Name:
Befetupitant |
CAS No.:
290296-68-3 |
| Purity:
99.94% |
Supply Ability:
10g |
| Release date:
2026/04/20 |
Product Introduction
Bioactivity
| Name | Befetupitant |
| Description | Befetupitant (Ro67-5930) is a potent and selective tachykinin 1 receptor (NK1R) antagonist for the study of corneal neovascularization. |
| In vivo | In the alkali burn model, Befetupitant, a highly selective NK1R antagonist, was tested. Hemangiogenesis and lymphangiogenesis were effectively reduced (P<0.05) after topical application of Befetupitant for 4 days at both concentrations (0.4 and 1.6 mg/mL). However, both Befetupitant and its vehicle DMSO induced corneal opacity even in healthy controls, as observed during slit-lamp examination. Furthermore, fluorescein and hematoxylin-eosin staining confirmed DMSO toxicity by revealing epithelial damage and inflammatory cellular infiltration in the stroma. Despite Befetupitant's effectiveness in reducing corneal neovascularization (CNV) in the alkali burn model, its toxicity due to the DMSO vehicle led to the decision not to test it in the suture model[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 6.88 mg/mL (12.17 mM), Sonication is recommended.
|
| Keywords | NK1R | NK1 | Neurokininreceptor | Neurokinin receptor | Befetupitant |
| Inhibitors Related | Maropitant citrate | Lanepitant 2HCl | Rolapitant | Ezlopitant | Octahydroisoindole | (R)-CJ 11974 | Netupitant | Aprepitant | Vofopitant dihydrochloride | Vofopitant | Fosaprepitant dimeglumine | Maropitant |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Neurotransmitter Receptor Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Fluorochemical Library | GPCR Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$490.00
|
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-04-20 |
United States